Ontology highlight
ABSTRACT:
SUBMITTER: Toulmonde M
PROVIDER: S-EPMC4478976 | biostudies-literature | 2015 Jul
REPOSITORIES: biostudies-literature
Toulmonde M M Le Cesne A A Piperno-Neumann S S Penel N N Chevreau C C Duffaud F F Bellera C C Italiano A A
Annals of oncology : official journal of the European Society for Medical Oncology 20150603 7
<h4>Background</h4>Preclinical data have suggested a therapeutic role of JUN pathway activation in dedifferentiated liposarcoma (DDLPS) tumorigenesis. Aplidin is a drug inducing apoptosis through a strong, sustained activation of c-Jun NH2-terminal kinase.<h4>Methods</h4>This phase II trial included patients with progressive advanced DDLPS. They received Aplidin 5 mg/m(2) days 1-15, 28-day cycle until disease progression or unacceptable toxicity. The primary end point was the 3-month nonprogress ...[more]